Adam Bero

Adam is an investor relation professional with deep scientific background, extensive experience working in world-renowned R&D organizations, and a track record of success advising biotech executives on all aspects of IR and corporate strategy.

Prior to joining Kendall Investor Relations, Adam was Chief of Staff to the CEO at Biogen – a role he was selected for following his work on Biogen’s IR team. As Chief of Staff, Adam served as a senior-level advisor to the CEO and prepared internal executive communications. Earlier, Adam was the R&D lead within the IR group, which was recognized by Institutional Investor Magazine as one of the Best IR teams in Biotechnology. Adam’s IR experience includes developing and delivering messaging around clinical data readouts, pipeline assets, and novel technologies, authoring earnings presentations and R&D investor presentations, and communicating directly to a broad range of investors and analysts.

Prior to his IR experience, Adam was a scientist at Biogen and Merck Research Laboratories where he led early-stage target validation and drug development programs with a focus on neurodegenerative diseases.

Before joining the industry, Adam completed a postdoctoral fellowship in the Department of Brain and Cognitive Sciences at MIT.